Search results
Results from the WOW.Com Content Network
The plasma half-life is about 35 to 40 hours when carbamazepine is given as single dose, but it is a strong inducer of liver enzymes, and the plasma half-life shortens to about 12 to 17 hours when it is given repeatedly. The half-life can be further shortened to 9–10 hours by other enzyme inducers such as phenytoin or phenobarbital. About 70% ...
Cenobamate, sold under the brand names Xcopri (US) and Ontozry (EU), is a medication used for the treatment of partial-onset seizures, a kind of epilepsy, in adults. [3] [7] [8] It is taken by mouth.
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
Esketamine (Spravato) – non-competitive NMDA receptor antagonist, other actions [13] Gepirone (Exxua) – 5-HT 1A receptor partial agonist and α 2-adrenergic receptor antagonist; Opipramol (Insidon) — σ 1 receptor agonist, other actions; Tianeptine (Stablon, Coaxil, Tianeurax) – weak and atypical μ-opioid receptor agonist, other actions
10–25 1.5 (90–111 minutes) Instantaneously (from 5 to 15 sec); 4× more rapid than fentanyl 0.25 hr (15 min); up to 54 minutes until offset of effects Trefentanil (10–25)+ Brifentanil (10–25)+ Acetylfentanyl: 15 7-Hydroxymitragynine: 17 ~0.6 mg Furanylfentanyl: 20 Butyrfentanyl: 25 Enadoline: 25
Other side effects include vision loss and dizziness. [3] It is a recommended treatment in pregnancy and appears to be safe for the baby. [4] [5] The World Health Organization; however, recommends waiting until after pregnancy for treatment when feasible. [2] It is made from 4-methyl-piperazine. [6]
Remacemide is a drug which acts as a low-affinity NMDA antagonist with sodium channel blocking properties. [2] It has been studied for the treatment of acute ischemic stroke, [3] [4] epilepsy, [5] Huntington's disease, and Parkinson's disease.
a Moderate inhibitor causes at least a 2-fold increase in the plasma AUC values, or 50–80% decrease in clearance. [39] a Weak inhibitor causes at least a 1.25-fold but less than 2-fold increase in the plasma AUC values, or 20–50% decrease in clearance. [39] The inhibitors of CYP3A4 are the following substances.